Opus Genetics, Inc. (IRD) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$16.48M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$14.36M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$8.31M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$8.91M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$16.48M | (m) | $755.00K | (m) | (m) | -$11.95M* | (m) | (m) | (m) | $0.00 |
| 2026-03-31 | Reported | (m) | -$14.36M | (m) | $2.16M | (m) | (m) | -$12.73M | (m) | (m) | (m) | $0.00 |
| 2025-09-30 | Reported | (m) | -$8.31M | (m) | $3.08M | (m) | (m) | -$6.16M* | (m) | (m) | (m) | $0.00 |
| 2025-06-30 | Reported | (m) | -$8.91M | (m) | $2.88M | (m) | (m) | -$10.27M* | (m) | (m) | (m) | $0.00 |
| 2025-03-31 | Reported | (m) | -$9.93M | (m) | $4.37M | (m) | (m) | -$8.99M | (m) | (m) | (m) | $0.00 |
| 2024-09-30 | Reported | (m) | -$8.01M | (m) | $3.87M | (m) | (m) | -$5.13M* | (m) | (m) | (m) | $0.00 |
| 2024-06-30 | Reported | (m) | -$8.33M | (m) | $1.11M | (m) | (m) | -$7.29M* | (m) | (m) | (m) | $0.00 |
| 2024-03-31 | Reported | (m) | -$7.71M | (m) | $1.71M | (m) | (m) | -$5.72M | (m) | (m) | (m) | $0.00 |
| 2023-09-30 | Reported | (m) | $6.39M | (m) | $11.94M | (m) | (m) | -$3.00M* | (m) | (m) | (m) | $14.00K |
| 2023-06-30 | Reported | (m) | -$5.39M | (m) | $3.67M | (m) | (m) | $989.00K* | (m) | (m) | (m) | $0.00 |
| 2023-03-31 | Reported | (m) | -$6.13M | (m) | $1.75M | (m) | (m) | -$3.65M | (m) | (m) | (m) | $0.00 |
| 2022-09-30 | Reported | (m) | -$4.54M | (m) | $0.00 | (m) | (m) | -$4.50M* | (m) | (m) | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$4.94M | (m) | $0.00 | (m) | (m) | -$3.81M* | (m) | (m) | (m) | $0.00 |
| 2022-03-31 | Reported | (m) | -$6.51M | (m) | $0.00 | (m) | (m) | -$6.17M | (m) | (m) | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$4.23M | (m) | $489.00K | (m) | (m) | -$3.58M* | (m) | (m) | (m) | $0.00 |
| 2021-06-30 | Reported | (m) | -$7.14M | (m) | $100.00K | (m) | (m) | -$4.33M* | (m) | (m) | (m) | $0.00 |
| 2021-03-31 | Reported | (m) | -$5.19M | (m) | (m) | (m) | (m) | -$5.81M | (m) | (m) | (m) | $0.00 |
| 2020-09-30 | Reported | (m) | -$1.95M | (m) | $0.00 | (m) | (m) | -$1.06M* | (m) | $149.59K | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$1.26M | (m) | $0.00 | (m) | (m) | -$651.00K* | (m) | $231.61K | (m) | $0.00 |
| 2020-03-31 | Reported | (m) | -$2.73M | (m) | (m) | (m) | (m) | -$732.00K | (m) | $456.79K | (m) | $0.00 |
| 2019-09-30 | Reported | (m) | -$2.28M | (m) | (m) | (m) | (m) | -$2.38M* | (m) | $1.13M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$2.99M | (m) | (m) | (m) | (m) | -$1.81M* | (m) | $1.65M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$3.94M | (m) | (m) | (m) | (m) | -$4.38M | (m) | $2.24M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$4.97M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$4.68M | (m) | (m) | (m) | (m) | -$4.17M* | (m) | $2.89M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$5.00M | (m) | (m) | (m) | (m) | -$4.45M* | (m) | $3.43M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$5.89M | (m) | (m) | (m) | (m) | -$5.60M | (m) | $4.06M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$4.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$4.22M | (m) | (m) | (m) | (m) | -$3.45M* | (m) | $2.64M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$4.28M | (m) | (m) | (m) | (m) | -$4.10M* | (m) | $2.54M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$3.95M | (m) | (m) | (m) | (m) | -$4.17M | (m) | $2.26M | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$3.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$3.72M | (m) | (m) | (m) | (m) | (m) | (m) | $2.30M | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$3.91M | (m) | (m) | (m) | (m) | (m) | (m) | $2.24M | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$4.86M | (m) | (m) | (m) | (m) | (m) | (m) | $3.47M | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$4.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$4.66M | (m) | (m) | (m) | (m) | (m) | (m) | $3.10M | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$4.82M | (m) | (m) | (m) | (m) | (m) | (m) | $3.24M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$4.42M | (m) | (m) | (m) | (m) | (m) | (m) | $2.89M | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$3.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$3.14M | (m) | (m) | (m) | (m) | (m) | (m) | $1.82M | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$3.51M | (m) | (m) | (m) | (m) | (m) | (m) | $1.70M | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$2.77M | (m) | (m) | (m) | (m) | (m) | (m) | $1.27M | (m) | $0.00 |
| 2013-09-30 | Reported | (m) | -$1.82M | (m) | (m) | (m) | (m) | (m) | (m) | $781.28K | (m) | $0.00 |
| 2013-06-30 | Reported | (m) | -$1.91M | (m) | (m) | (m) | (m) | (m) | (m) | $925.13K | (m) | $0.00 |
| 2013-03-31 | Reported | (m) | -$1.91M | (m) | (m) | (m) | (m) | (m) | (m) | $552.47K | (m) | $0.00 |
| 2012-09-30 | Reported | (m) | -$1.80M | (m) | (m) | (m) | (m) | (m) | (m) | $1.07M | (m) | $0.00 |
| 2012-06-30 | Reported | (m) | -$1.85M | (m) | (m) | (m) | (m) | (m) | (m) | $1.02M | (m) | $0.00 |
| 2012-03-31 | Reported | (m) | -$1.88M | (m) | (m) | (m) | (m) | (m) | (m) | $1.04M | (m) | $0.00 |
| 2011-09-30 | Reported | (m) | -$3.36M | (m) | (m) | (m) | (m) | (m) | (m) | $2.37M | (m) | $0.00 |
| 2011-06-30 | Reported | (m) | -$6.46M | (m) | (m) | (m) | (m) | (m) | (m) | $5.42M | (m) | $0.00 |
| 2011-03-31 | Reported | (m) | -$3.91M | (m) | (m) | (m) | (m) | (m) | (m) | $2.72M | (m) | $0.00 |
| 2010-09-30 | Reported | (m) | -$2.37M | (m) | (m) | (m) | (m) | (m) | (m) | $671.34K | (m) | $0.00 |
| 2010-06-30 | Reported | (m) | -$3.19M | (m) | (m) | (m) | (m) | (m) | (m) | $1.33M | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$38.60M | (m) | $14.20M | (m) | (m) | -$35.25M | (m) | (m) | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$62.07M | (m) | $10.99M | (m) | (m) | -$25.58M | (m) | (m) | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$10.56M | (m) | $19.05M | (m) | (m) | -$1.11M | (m) | (m) | (m) | $12.00K |
| 2022-12-31 | Reported | (m) | $18.23M | (m) | $39.85M | (m) | (m) | $14.31M | (m) | (m) | (m) | $315.00K |
| 2021-12-31 | Reported | (m) | -$22.70M | (m) | $589.00K | (m) | (m) | -$19.37M | (m) | (m) | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$19.97M | (m) | $0.00 | (m) | $0.00 | -$6.80M | (m) | (m) | (m) | $0.00 |
| 2019-12-31 | Reported | (m) | -$4.19M | (m) | (m) | (m) | $25.00K | -$3.59M | (m) | $5.48M | (m) | $0.00 |
| 2019-09-30 | Rolling | (m) | -$14.17M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | Rolling | (m) | -$16.58M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | Rolling | (m) | -$18.59M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$20.54M | (m) | (m) | (m) | (m) | -$18.84M | (m) | $13.11M | (m) | (m) |
| 2018-12-31 | Rolling | (m) | -$20.54M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Rolling | (m) | -$20.47M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | Rolling | (m) | -$20.00M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | Rolling | (m) | -$19.29M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$17.35M | (m) | (m) | (m) | (m) | -$15.42M | (m) | $10.72M | (m) | (m) |
| 2017-12-31 | Rolling | (m) | -$17.35M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | Rolling | (m) | -$16.38M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | Rolling | (m) | -$15.87M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | Rolling | (m) | -$15.50M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$16.41M | (m) | (m) | (m) | (m) | (m) | (m) | $10.09M | (m) | (m) |
| 2016-12-31 | Rolling | (m) | -$16.41M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | Rolling | (m) | -$16.86M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | Rolling | (m) | -$17.80M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | Rolling | (m) | -$18.71M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$18.26M | (m) | (m) | (m) | (m) | (m) | (m) | $12.15M | (m) | (m) |
| 2015-12-31 | Rolling | (m) | -$18.26M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | Rolling | (m) | -$17.75M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | Rolling | (m) | -$16.23M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | Rolling | (m) | -$14.92M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$13.27M | (m) | (m) | (m) | (m) | (m) | (m) | $7.02M | (m) | (m) |
| 2014-12-31 | Rolling | (m) | -$13.27M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$7.98M | (m) | (m) | (m) | (m) | (m) | (m) | $3.25M | (m) | $0.00 |
| 2012-12-31 | Reported | (m) | -$6.58M | (m) | (m) | (m) | (m) | (m) | (m) | $3.39M | (m) | $0.00 |
| 2011-12-31 | Reported | (m) | -$16.13M | (m) | (m) | (m) | (m) | (m) | (m) | $11.99M | (m) | $0.00 |
| 2010-12-31 | Reported | (m) | -$10.31M | (m) | (m) | (m) | (m) | (m) | (m) | $3.93M | (m) | $0.00 |
| 2009-12-31 | Reported | (m) | -$6.47M | (m) | (m) | (m) | (m) | (m) | $100.00K | $3.18M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |